


Testing of the Guidance on Risk Assessment of Living Modified Organisms

#8



COMPLETE

Collector: BCH website (Website Survey)

Started: Monday, March 31, 2014 10:28:43 AM

Last Modified: Monday, March 31, 2014 10:31:19 AM

Time Spent: 00:02:36

PAGE 1

Q1: Type of submission:

Organization

PAGE 2

Q2: Name of the Party:

Respondent skipped this question

Q3: Person submitting this questionnaire:

Respondent skipped this question

Q4: Institution(s) or organization(s) that participated in the testing:

Respondent skipped this question

Q5: Context in which the testing was conducted

Respondent skipped this question

Q6: Actual case(s) of risk assessment used in the testing:
Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Respondent skipped this question

Q7: In what language was the Guidance tested?

Respondent skipped this question

PAGE 3

Q8: Name of the other Government:

Respondent skipped this question

Q9: Person submitting this questionnaire:

Respondent skipped this question

Q10: Institution(s) or organization(s) that participated in the testing:

Respondent skipped this question

Q11: Context in which the testing was conducted

Respondent skipped this question

Q12: Actual case(s) of risk assessment used in the testing:
Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Respondent skipped this question

Q13: In what language was the Guidance tested?

Respondent skipped this question

Q14: Name of the organization:	State University of Moldova
Q15: Person submitting this questionnaire:	
Full Name:	Mihai Lesanu
Email Address:	mglesanu@yahoo.com
Q16: Institution(s) or organization(s) that participated in the testing:	Academic institution(s)
Q17: Context in which the testing was conducted	Group event(s) (e.g., workshop, training course, meeting)
Q18: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml?documentid=104904 and http://bch.cbd.int/database/record.shtml?documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.	
Risk Assessment 1:	http://bch.cbd.int/database/record.shtml?documentid=104904
Q19: In what language was the Guidance tested?	Other (please specify): English and Russian

Q20: Would you like to submit an evaluation of the following section of the Guidance: Part I: The Roadmap for Risk Assessment	Yes
--	-----

Q21: This section of the Guidance is practical.1	
(no label)	Strongly Agree
Q22: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q23: This section of the Guidance is useful or has utility.2	
(no label)	Strongly Agree
Q24: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	
We consider important to include human health considerations as part of Roadmap on risk assessment of LMOs.	
Q25: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	
(no label)	Strongly Agree
Q26: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	
We suggest to reflect special provision and characteristics of donor organisms under lines 441-443 of the Roadmap, as it is requested in the Annex III of the Protocol.	

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q27: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Strongly Agree

Q28: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

These references materials might be updated and completed any time, so the new ly scientific evidence is available to use during the risk assessment.

Q29: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

The State University of Moldova, Faculty of Biology and Pedology consider that the Roadmap on risk assessment is an extremely practical, useful and efficient document that can be very helpful for my country to develop institutional and personnel capacities for risk assessment and decision making on LMOs.

The testing of the Roadmap was carried out during the Eastern European Regional Course on Integrative Impact Assessment of LMOs under the Cartagena Protocol "Advancing LMO assessment: Principles, Practice and Progress", that was held during 3-8 February 2014 in Chisinau, Republic of Moldova. The overall understanding of participants from the State University of Moldova is that the Roadmap is extremely useful, practical and efficient to guide national evaluators in the risk assessment process.

The Roadmap is fully consistent with the provisions of the Cartagena protocol and its Annex III. It is to be mentioned that the Roadmap is very well structured, it contains information that reflect fundamental knowledge of various fields/disciplines of science. It is written in scientific language but at the same time it is clear and understandable for decision makers and risk evaluators.

PAGE 7

Q30: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LMOs with stacked genes or traits

Yes

PAGE 8

Q31: This section of the Guidance is practical.1

(no label)

Strongly Agree

Q32: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q33: This section of the Guidance is useful or has utility.2

(no label)

Strongly Agree

Q34: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q35: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Strongly Agree

Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q37: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Strongly Agree

Q38: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q39: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 9

Q40: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM crops with tolerance to abiotic stress

No

PAGE 10

Q41: This section of the Guidance is practical.1

Respondent skipped this question

Q42: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q43: This section of the Guidance is useful or has utility.2

Respondent skipped this question

Q44: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q45: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

Respondent skipped this question

Q46: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q47: This section of the Guidance takes into account past and present experiences with LMOs.4

Respondent skipped this question

Q48: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q49: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 11

Q50: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM mosquitoes

No

PAGE 12

Q51: This section of the Guidance is practical.1	<i>Respondent skipped this question</i>
Q52: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q53: This section of the Guidance is useful or has utility.2	<i>Respondent skipped this question</i>
Q54: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q55: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3	<i>Respondent skipped this question</i>
Q56: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q57: This section of the Guidance takes into account past and present experiences with LMOs.4	<i>Respondent skipped this question</i>
Q58: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q59: Here you may provide further details to explain your answers in evaluating this section of the Guidance:	<i>Respondent skipped this question</i>

PAGE 13

Q60: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM trees	No
--	----

PAGE 14

Q61: This section of the Guidance is practical.1	<i>Respondent skipped this question</i>
Q62: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q63: This section of the Guidance is useful or has utility.2	<i>Respondent skipped this question</i>
Q64: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q65: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

Respondent skipped this question

Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q67: This section of the Guidance takes into account past and present experiences with LMOs.4

Respondent skipped this question

Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q69: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 15

Q70: Would you like to submit an evaluation of the following section of the Guidance: Part III: Monitoring of LMOs Released into the Environment

No

PAGE 16

Q71: This section of the Guidance is practical.1

Respondent skipped this question

Q72: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q73: This section of the Guidance is useful or has utility.2

Respondent skipped this question

Q74: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q75: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

Respondent skipped this question

Q76: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q77: This section of the Guidance takes into account past and present experiences with LMOs.4

Respondent skipped this question

Q78: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q79: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

Q80: Would you like to submit an evaluation of the following section of the Guidance: Background Documents No

Q81: This section of the Guidance is practical.1 *Respondent skipped this question*

Q82: This section of the Guidance is useful or has utility.2 *Respondent skipped this question*

Q83: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 *Respondent skipped this question*

Q84: This section of the Guidance takes into account past and present experiences with LMOs.4 *Respondent skipped this question*

Q85: Please use the space below if you wish to provide additional feedback regarding the testing of the Guidance on Risk Assessment of Living Modified Organisms: *Respondent skipped this question*